Immunic reports Phase 2 CALLIPER extension data for vidofludimus calcium in progressive MS through week 48
Immunic flagged new Phase 2 CALLIPER open-label extension results for vidofludimus calcium in progressive multiple sclerosis, with low discontinuation rates through week 48; data to be presented Oct. 21-23 at MSToronto2026.